Outcomes of the tacrolimus drug-eluting Janus stent: a prospective two-centre registry in high-risk patients

Romagnoli, Enrico; Leone, Antonio Maria; Burzotta, Francesco; Trani, Carlo; Angeloni, Giulia; Materazzo, Guido; Niccoli, Giampaolo; Maria, De Vita; Perfetti, Matteo; Mazzari, Mario Attilio; Mongiardo, Rocco; Rebuzzi, Antonio Giuseppe; Schiavoni, Giovanni; Crea, Filippo

doi:10.2459/jcm.0b013e3282f20ad1

Cited by 10 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, we excluded studies involving other elution technologies (for example, reservoirs sealed by bioabsorbable polymers). The exclusion of reservoir-based BP-DES aimed to reduce the heterogeneity of our analysis since the published results of reservoir technologies have been disappointing [27][28][29]63 causing most of these DES to be dropped from the market. Furthermore in our meta-analysis we could not include other BP-DES with similar technology like the paclitaxel BP-DES Infinnium TM stent and the sirolimus BP-DES Excel TM stent due to the absence of…”

Section: Discussionmentioning

confidence: 99%

Biodegradable versus durable polymer drug eluting stents in coronary artery disease: Insights from a meta-analysis of 5834 patients

Lupi

Rognoni

Secco

et al. 2012

Eur J Prev Cardiolog

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Biodegradable versus durable polymer drug eluting stents in coronary artery disease: Insights from a meta-analysis of 5834 patients

Lupi

Rognoni

Secco

et al. 2012

Eur J Prev Cardiolog

View full text Add to dashboard Cite

show abstract

“…In contrast, the data obtained in the Carbostent‐Trial37 did not prove any advantage of the Carbofilm‐coated stent over uncoated stainless steel stents. Moreover, outcomes from the tacrolimus‐eluting carbofilm‐coated stent showed a higher incidence of major adverse cardiac events (MACE) and stent thrombosis higher than that in previous studies on DES 38. It has to be mentioned that the name “carbon coatings” relates to a group of coatings with very different properties.…”

Section: Discussionmentioning

confidence: 94%

“…Diamond like carbon (DLC) is a name for coatings which contain certain amount of sp 3 bonds in addition to sp 2 bonds. Amorphous hydrogenated DLC is also widely used for coating of medical devices including cardiovascular stents, such as Phytis™ stent (Phytis Medical Devices GmbH, Berlin, Germany) 36, 38. The amorphous hydrogenated DLC coatings is usually prepared by plasma enhanced chemical vapor deposition (PECVD) methods with methane or acetylene as carbon precursors.…”

Section: Discussionmentioning

confidence: 99%

“…The properties of coating can be adjusted significantly by optimization of the deposition parameters. In recent years DLC was also reported for use as a drug delivery coating 38. Although high corrosion resistance and good biocompatibility make the DLC coating a promising candidate for cardiovascular application, some uncertainties with the adhesion strength of the carbon coatings to the metallic surface have been reported.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Inorganic coatings for cardiovascular stents: In vitro and in vivo studies

et al. 2010

View full text Add to dashboard Cite

The in-vitro and in-vivo biocompatibility of two oxides (TiO and ZrO) and diamond-like carbon (D) coated stents has been assessed and compared with uncoated stainless steel (St) stents. In vitro studies demonstrated that both fibrinogen adsorption and platelet adhesion were significantly higher on D coating compared to those on oxide coatings and uncoated stainless steel. In addition TiO and ZrO coatings showed evidence of a minor inflammatory response and more complete endothelialization of the aorta than that seen around D coated and uncoated St stents. The resulting neointimal growth in the aorta with TiO, ZrO, and D coated and uncoated St stents, measured 8 weeks after stenting (the ratio of the neointima in the stented artery to the non-stented artery) was 1.03 + 0.28, 0.85 + 0.36, 1.78 + 1.26, and 1.15 + 0.56, accordingly. From the data obtained it could be concluded that the increased neointima measured around D-coated stents, may be due to both, the inferior haemocompatibility of the diamond-like carbon coating and mechanical instability of D coating observed in an in vivo environment.

show abstract

“…To date, two clinical trials evaluating the safety and efficacy of tacrolimus-eluting stents (Janus ® ; Sorin, Saluggia, Italy) have been completed: European Direct Stenting of de novo Coronary Artery Stenosis With Tacrolimus-Eluting Versus Carbon-Coated Carbostents (JUPITER) I, a first-in-man study, and JUPITER II [18], a randomized, controlled study that compared the Janus stent with its bare-metal stent counterpart. Safety concerns regarding clinical usage of tacrolimus-eluting stents have recently been reported in two registries [19,20].…”

mentioning

confidence: 99%

Evolution of stents: past, present and future

Tamburino

Capodanno

2009

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

The rationale for the introduction of drug-eluting stents was to reduce the formation of neointimal hyperplasia, a proliferative maladaptive healing response to bare-metal stent implantation, with the potential of leading to restenosis and repeat revascularization."The introduction of metallic stents to treat coronary artery disease has been one of the most revolutionary breakthroughs in the history of cardiology. In the early stages of their development, these devices were mainly considered to represent the mechanical solution to abrupt vessel closure and elastic recoil following balloon angio plasty. For this reason, research and debate initially focused on issues surrounding stent design, including the assessment of different materials and surface treatments. More recently, following the introduction of drug-eluting stents (DESs), the debate has shifted to the research of the best vector for local drug delivery and modification of coronary plaque pathophysiology. The rationale for the introduction of DESs was to reduce the formation of neo intimal hyperplasia, a proliferative mal adaptive healing response to bare-metal stent implantation, potentially leading to restenosis and repeat revascularization. To date, six limus family-related drugs are currently being studied in DES, namely sirolimus, everolimus, biolimus A9, zotarolimus, tacrolimus and pimecrolimus. Another non-limus-family-related drug that is studied widely for its efficacy in coronary stents is paclitaxel. While the effect of limus family-related drugs depends on blockage of the cell cycle, mainly of the smooth muscle cell, from the G 1 to S phase (i.e., sirolimus, everolimus, biolimus A9 and zotarolimus) or the inhibition of T-cell activation (i.e., tacrolimus and pimerolimus), the activity of paclitaxel has been explained by its ability to stabilize microtubules and, thereby, inhibit cell division in the G 0 /G 1 and G 2 /M phases.

show abstract

Outcomes of the tacrolimus drug-eluting Janus stent: a prospective two-centre registry in high-risk patients

Cited by 10 publications

References 15 publications

Biodegradable versus durable polymer drug eluting stents in coronary artery disease: Insights from a meta-analysis of 5834 patients

Biodegradable versus durable polymer drug eluting stents in coronary artery disease: Insights from a meta-analysis of 5834 patients

Inorganic coatings for cardiovascular stents: In vitro and in vivo studies

Evolution of stents: past, present and future

Contact Info

Product

Resources

About